Dexamethasone Sodium Phosphate

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM). “Initiating the Phase 2 MOMENTUM trial, which builds upon the compelling anti-myeloma activity and differentiated safety pro in the Phase 1 trial, is a critical step for cemsidomide to become a foundational therapy for multiple myeloma patients, who are in need of a safe, oral, and convenient treatment option,” said Len Reyno, chief medical officer of C4 Therapeutics. “With this milestone accomplished, we are also on track to initiate the Phase 1b trial of cemsidomide in combination with elranatamab in the second quarter, as we continue to advance our regulatory strategy that could deliver two accelerated approval paths in multiple myeloma.” The Phase 2 MOMENTUM trial is an open-label, single-arm, multicenter study to assess anti-myeloma activity and further characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone in RRMM patients for the fourth line or later. The trial will enroll approximately 100 patients to evaluate cemsidomide at the 100 µg dose level. Cemsidomide is administered with a daily dosing schedule of 14 days on and 14 days off, and dexamethasone is dosed once a week. The primary endpoint is the overall response rate per the International Myeloma Working Group response criteria as assessed by an independent review committee. Secondary endpoints will evaluate a range of additional safety and efficacy measures. The Phase 2 MOMENTUM trial is part of a broader development strategy for cemsidomide, which also includes a Phase 1b study of cemsidomide in combination with elranatamab (ELREXFIO ® ). Elranatamab is an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. Together, these trials support cemsidomide’s use across multiple lines of treatment. ANTICIPATED UPCOMING MILESTONES Phase 1b trial of cemsidomide in combination with elranatamab is on track to initiate in Q2 2026. Further analysis of the completed Phase 1 trial of cemsidomide in combination with dexamethasone is expected in mid-2026. Enrollment for Phase 2 MOMENTUM trial is expected to be completed in Q1 2027. About Cemsidomide Cemsidomide is an investigational, orally bioavailable molecular glue degrader (MonoDAC ® degrader) of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the Phase 1 trial, which has completed enrollment, show cemsidomide’s differentiated safety and tolerability pro potentially class-leading anti-myeloma activity that support the potential for durable outcomes. About the MOMENTUM Trial MOMENTUM (Multi-center trial Of cemsidoMidE iN relapsed/refracTory mUltiple Myeloma) is a Phase 2, open-label, single-arm, study to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Data from the Phase 1 trial identified 100 µg as the recommended Phase 2 dose. The primary endpoint is overall response rate per International Myeloma Working Group response criteria, as assessed by an independent review committee. Approximately 100 patients who have received at least three prior anti-myeloma regimens that must have included an IKZF1/3 degrader, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager or CAR-T therapy will be enrolled in the trial. More information is available at clinicaltrials.gov (NCT07284758). About Cemsidomide in Combination With Elranatamab (ELREXFIO ® ) The Phase 1b trial is designed to evaluate the safety, tolerability and preliminary efficacy of cemsidomide in combination with elranatamab, an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. The study will evaluate different cemsidomide dose levels (beginning with 75 µg, with the opportunity to simultaneously explore 50 µg and 100 µg) in patients who have received one to four prior lines of therapy, which must have consisted of at least one IKZF1/3 degrader. Exclusion criteria for patients include those who have received prior treatment with a BCMA-directed T-cell engager or BCMA-directed CAR-T therapy. More information is available at clinicaltrials.gov (NCT07280013). About Multiple Myeloma Multiple myeloma (MM) is a rare blood cancer affecting plasma cells. Approximately 36,000 people in the United States are diagnosed with MM each year. Approved IKZF1/3 degraders remain foundational therapies across lines of MM treatment. Despite advances, including immune-directed approaches, most patients ultimately relapse, underscoring a growing need for new therapeutics options that continue to leverage IKZF1/3 degradation to drive myeloma cell death and T-cell activation. About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit . Forward Looking Statements This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO ® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC ® degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement and patient enrollment; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to replicate interim or early-stage results from our clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials; regulatory developments in the United States and foreign countries; the anticipated timing and content of presentations of data from our clinical trials; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. Contacts: Investors: Courtney Solberg Associate Director, Investor Relations CSolberg@c4therapeutics.com Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com

iStock, Mininyx Doodle The centerpiece of the takeover is anito-cel, a CAR T therapy under development for relapsed or refractory multiple myeloma. An FDA decision on the therapy is expected by December 2026. Just days after CEO Daniel O’Day told investors M&A was not an urgent priority for the pharma, Gilead is dropping $7.8 billion to swallow its CAR T partner Arcellx ahead of a potential approval later this year. Gilead’s offer values Arcellx at $115 per share, a 68% premium on the biotech’s volume-weighted average share price over the last 30 days, according to Gilead’s Monday announcement . The pharma has also tacked on a one-time nontransferable contingent value right that entitles Arcellx shareholders to $5 more per share that they hold, payable if a certain commercial milestone is hit. The companies expect to close the transaction in the second quarter of this year. Earnings Gilead To Stay ‘Proactive And Disciplined’ With Deals But M&A Not Urgent Priority With 10 launches planned in the coming quarters, Gilead isn’t feeling the same acquisition urgency as its pharma peers—though the prospect of a takeover isn’t off the table. February 11, 2026 · 2 min read · Tristan Manalac At the heart of Monday’s agreement is anitocabtagene autoleucel, also called anito-cel, an investigational CAR T therapy that targets the BCMA protein to treat relapsed or refractory multiple myeloma. The drug is currently under FDA review with a target action date of Dec. 23, 2026, Gilead said on Monday. Data from the pivotal Phase 2 iMMagine-1 study support the drug’s regulatory run. Results released in May 2025 demonstrated a 97% overall response rate , with complete response or stringent complete response reaching 68%. Progression-free and overall survival rates at six months were 91.9% and 96.6%, respectively. Gilead and Arcellx are also running the Phase 3 iMMagine-3 study, pitting anito-cel against standard of care, including pomalidomide, bortezomib and dexamethasone. The trial, which aims to enroll 450 patients with relapsed or refractory multiple myeloma who have undergone one to three prior lines of therapy, has a primary completion date of July 2028. The companies first linked up in December 2022, with the pharma through its Kite subsidiary fronting $225 million and making a $100 million equity investment into Arcellx. The agreement, which centered on anito-cel, also included a pledge of up to $3.9 billion in milestones. After almost a year, Gilead in November 2023 deepened its commitment to Arcellx for an additional $85 million in cash and $200 million in equity investments, plus the promise of unspecified milestones. Monday’s Arcellx acquisition follows a similarly hefty cell therapy contract in October 2025, when Gilead partnered with China’s Pregene for $120 million upfront and up to $1.52 billion in milestones. Then, in January, the pharma put $300 million on the line to collaborate with Texas-based OncoNano Medicine on developing novel cancer drugs.